TCR2 ended the fourth quarter of 2022 with $149.2M in cash, cash equivalents, and investments compared to $265.6M as of December 31, 2021. Net cash used in operations was $25M for the fourth quarter of 2022 compared to $23.3M for the fourth quarter of 2021.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TCRR:
- TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
- TCR2 Therapeutics downgraded to Hold from Buy at Jefferies
- TCR2 Therapeutics downgraded to Hold from Buy at Truist
- TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Adaptimmune downgraded to Hold from Buy at JonesResearch